1 day+7.39%
1 week+47.37%
Current month+51.35%
1 month+53.80%
3 months+78.73%
6 months+95.72%
1 week 87.4
Extreme 87.4
130.5
1 month 76.7
Extreme 76.7
130.5
Current year 37.55
Extreme 37.55
130.5
1 year 37.55
Extreme 37.55
130.5
3 years 37.55
Extreme 37.55
130.5
5 years 37.55
Extreme 37.55
130.5
10 years 37.55
Extreme 37.55
130.5
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 13/01/2017
Chief Executive Officer - 13/01/2017
Director of Finance/CFO - 23/09/2019
Director TitleAgeSince
Director/Board Member 52 25/07/2019
Chairman - 13/01/2017
Director/Board Member - 23/10/2025
Change 5-day change 1-year change 3-year change Capi.($)
+7.39%+47.37% - - 483M
+0.68%-2.28%+2.16%+19.70% 48.42B
+4.07%+2.43%+483.70%+623.80% 43.66B
+4.33%+0.98%+12.80%+88.53% 39.51B
+1.94%-0.31%+26.24%+12.62% 38.95B
-0.50%0.00%+20.60%+60.49% 32.61B
-0.44%-3.22% - - 16.32B
+3.22%-0.88%+30.42%+135.47% 16.15B
-0.62%-0.06%+3.46%+27.74% 14.16B
+2.35%+3.48%+82.95%+43.41% 13.37B
Average +2.24%+3.42%+82.79%+126.47% 26.36B
Weighted average by Cap. +1.94%+0.10%+101.58%+151.17%

Financials

2024 2025
Net sales 803K 25.22K 21.77K 20.42K 18.6K 34.98K 2.41M 35.46K 239K 93.81K 1.21M 94.67K 92.62K 4.02M 50.29M 1.58M 1.36M 1.28M 1.16M 2.19M 151M 2.22M 14.99M 5.87M 75.64M 5.93M 5.8M 252M
Net income -440M -13.83M -11.94M -11.2M -10.2M -19.18M -1.32B -19.44M -131M -51.44M -662M -51.91M -50.79M -2.2B -1.11B -34.75M -30M -28.14M -25.63M -48.19M -3.32B -48.86M -330M -129M -1.66B -130M -128M -5.54B
Net Debt - -
Logo Elixiron Immunotherapeutics (Cayman) Limited
Elixiron Immunotherapeutics Cayman Ltd is an investment holding company located in Taiwan, focusing on developing innovative precision immunotherapy drugs for multiple diseases. The Company operates as a new drug research and development enterprise, with products currently in clinical development. Its pipeline is centered on innovative drug development, covering neurodegenerative disorders, immune-related diseases, and oncology. The main clinical-stage candidates are EI-1071 (Enrupatinib) and EI-001 (Indemakitug). EI-1071 (Enrupatinib) is a proprietary small-molecule drug targeting neurodegenerative diseases, with Alzheimer’s disease as its primary indication, currently in Phase II clinical trials. EI-001 (Indemakitug) is an anti-IFNy monoclonal antibody designed for precise immunomodulation in autoimmune diseases.
Employees
-
Date Price Change Volume
17/08/26 TWD 123.50 +7.39% 4,668,324
14/08/26 TWD 115.00 +20.80% 6,061,484
13/08/26 TWD 95.20 +1.38% 1,739,987
12/08/26 TWD 93.90 +1.84% 2,841,765
11/08/26 TWD 92.20 +10.02% 2,818,076
  1. Stock Market
  2. Stocks
  3. 7871 Stock